These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 3937731)

  • 1. Status of a group B Neisseria meningitidis vaccine.
    Frasch CE
    Eur J Clin Microbiol; 1985 Dec; 4(6):533-6. PubMed ID: 3937731
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vaccines against Neisseria meningitidis].
    Ferrón L; Criado MT; Ferreirós CM
    Enferm Infecc Microbiol Clin; 1992 May; 10(5):296-301. PubMed ID: 1391002
    [No Abstract]   [Full Text] [Related]  

  • 3. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccines for prevention of meningococcal disease.
    Frasch CE
    Clin Microbiol Rev; 1989 Apr; 2 Suppl(Suppl):S134-8. PubMed ID: 2497956
    [No Abstract]   [Full Text] [Related]  

  • 5. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine.
    Milagres LG; Gorla MC; Rebelo MC; Barroso DE
    FEMS Immunol Med Microbiol; 2000 Aug; 28(4):319-27. PubMed ID: 10891656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study.
    Noronha CP; Struchiner CJ; Halloran ME
    Int J Epidemiol; 1995 Oct; 24(5):1050-7. PubMed ID: 8557439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal meningitis.
    Lancet; 1989 Mar; 1(8639):647-8. PubMed ID: 2564462
    [No Abstract]   [Full Text] [Related]  

  • 8. Defences against meningococcal infections.
    Lancet; 1985 Oct; 2(8461):929-30. PubMed ID: 2865427
    [No Abstract]   [Full Text] [Related]  

  • 9. [Active immunization against serogroup B Neisseria meningitidis].
    Navarro-Alonso JA
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):513-9. PubMed ID: 14572386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease.
    Fischer M; Carlone GM; Holst J; Williams D; Stephens DS; Perkins BA
    Vaccine; 1999 May; 17(19):2377-83. PubMed ID: 10392619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neisseria meningitidis: vaccines and vaccine candidates.
    Al'Aldeen AA; Cartwright KA
    J Infect; 1996 Nov; 33(3):153-7. PubMed ID: 8945702
    [No Abstract]   [Full Text] [Related]  

  • 12. Current status of meningococcal group B vaccine candidates: capsular or noncapsular?
    Diaz Romero J; Outschoorn IM
    Clin Microbiol Rev; 1994 Oct; 7(4):559-75. PubMed ID: 7834605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiology. A furtive pathogen revealed.
    Nassif X
    Science; 2000 Mar; 287(5459):1767-8. PubMed ID: 10755929
    [No Abstract]   [Full Text] [Related]  

  • 14. Vaccines against meningococcal meningitis: current status.
    Epidemiol Bull; 1994 Jul; 15(2):13-5. PubMed ID: 8086300
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.
    Bjune G; Høiby EA; Grønnesby JK; Arnesen O; Fredriksen JH; Halstensen A; Holten E; Lindbak AK; Nøkleby H; Rosenqvist E
    Lancet; 1991 Nov; 338(8775):1093-6. PubMed ID: 1682541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-meningococcal vaccine: myth and reality].
    Nassif X
    Arch Pediatr; 1999; 6 Suppl 3():647s-649s. PubMed ID: 10429807
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine.
    Rosenqvist E; Høiby EA; Bjune G; Aase A; Halstensen A; Lehmann AK; Paulssen J; Holst J; Michaelsen TE; Nøkleby H; Frøholm LO; Closs O
    Dev Biol Stand; 1998; 92():323-33. PubMed ID: 9554288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The outlook for the development of a vesicular meningococcal serogroup B vaccine].
    Del'vig AA; Semenov BF
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (1):91-6. PubMed ID: 9532701
    [No Abstract]   [Full Text] [Related]  

  • 19. [Preventive effectiveness of an urgent mass vaccination with purified meningococcal polysaccharide vaccine observed during a meningitis epidemic].
    Wu C
    Zhonghua Liu Xing Bing Xue Za Zhi; 1985 Dec; 6(6):344-6. PubMed ID: 3938683
    [No Abstract]   [Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity of a quadrivalent combined meningococcal polysaccharide vaccine in children.
    Lepow ML; Beeler J; Randolph M; Samuelson JS; Hankins WA
    J Infect Dis; 1986 Dec; 154(6):1033-6. PubMed ID: 3097160
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.